| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7083808 | RHODES PHARMS | Controlled/modified release oral methylphenidate formulations |
Dec, 2019
(4 years ago) | |
| US10039719 | RHODES PHARMS | Methods of treating attention deficit hyperactivity disorder |
Dec, 2019
(4 years ago) | |
| US9066869 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US7247318 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US8580310 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US9801823 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US6419960 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US7438930 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US10463624 | RHODES PHARMS | Controlled release formulations |
Dec, 2019
(4 years ago) | |
|
US9066869 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US6419960 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US9801823 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US10039719 (Pediatric) | RHODES PHARMS | Methods of treating attention deficit hyperactivity disorder |
Jun, 2020
(3 years ago) | |
|
US7083808 (Pediatric) | RHODES PHARMS | Controlled/modified release oral methylphenidate formulations |
Jun, 2020
(3 years ago) | |
|
US8580310 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US7438930 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US7247318 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
Aptensio Xr is owned by Rhodes Pharms.
Aptensio Xr contains Methylphenidate Hydrochloride.
Aptensio Xr has a total of 17 drug patents out of which 17 drug patents have expired.
Expired drug patents of Aptensio Xr are:
- US7083808
- US10039719
- US9066869
- US7247318
- US8580310
- US9801823
- US6419960
- US7438930
- US10463624
- US9066869*PED
- US6419960*PED
- US9801823*PED
- US10039719*PED
- US7083808*PED
- US8580310*PED
- US7438930*PED
- US7247318*PED
Aptensio Xr was authorised for market use on 17 April, 2015.
Aptensio Xr is available in capsule, extended release;oral dosage forms.
Aptensio Xr can be used as method of treating attention deficit hyperactivity disorder (adhd).
The generics of Aptensio Xr are possible to be released after 16 June, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 17, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 April, 2015
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APTENSIO XR family patents
